TrialThe oncologist2019
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Lecia V Sequist et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this papercites it